in the world by sales, has diversified and grown bigger through mega-mergers, including the $68 billion purchase of Wyeth in 2009. But low productivity in its research and development efforts?coupled with patent expirations for top-selling drugs?has put...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer's Profit Rises 10% Amid Lower Costs
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account